Kristen Oelschlager Sells 8,586 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 8,586 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $24.42, for a total value of $209,670.12. Following the completion of the sale, the chief operating officer owned 21,874 shares of the company’s stock, valued at $534,163.08. This trade represents a 28.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Shares of CSTL opened at $23.83 on Wednesday. The business’s fifty day moving average price is $21.53 and its 200 day moving average price is $28.35. Castle Biosciences, Inc. has a 12-month low of $14.59 and a 12-month high of $44.28. The stock has a market capitalization of $722.76 million, a PE ratio of -54.16 and a beta of 1.00. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). The firm had revenue of $84.23 million during the quarter, compared to analyst estimates of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. Equities research analysts forecast that Castle Biosciences, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Castle Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Federated Hermes Inc. acquired a new stake in Castle Biosciences in the 4th quarter valued at approximately $26,000. Kemnay Advisory Services Inc. acquired a new position in Castle Biosciences during the 4th quarter worth $35,000. Jones Financial Companies Lllp grew its stake in shares of Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after purchasing an additional 2,648 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Castle Biosciences by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after purchasing an additional 297 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in shares of Castle Biosciences by 63.7% during the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after purchasing an additional 976 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CSTL. Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. BTIG Research lowered their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Canaccord Genuity Group dropped their price target on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Wall Street Zen lowered Castle Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Robert W. Baird cut their target price on Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.43.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.